ARMO BioSciences, Inc., a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) Orphan Drug designation for the treatment of pancreatic cancer.
The Agency also granted Fast Track designation for AM0010 in combination with FOLFOX as a second line therapy in patients with advanced metastatic pancreatic cancer. Read more . . .